A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)
Principal Investigator: Dr. Martin Schoen
Study Coordinators: Carley Browning
The purpose of this study is to learn about the investigational medicine called PH-06821497 (mevrometostat) in men with mCRPC who were previously treated with abiraterone acetate for prostate cancer.
This study is to evaluate whether the addition of EZH2 (enhancer of zeste homologue-2) inhibition to enzalutamide can reverse anti-androgen resistance, thereby in increasing the duration of clinical benefit of enzalutamide in participants who have previously been treated with abiraterone. This Phase 3 randomized study (C2321014) is designed to demonstrate the PT-06821497 plus enzalutamide provides superior clinical benefit compared to physician's choice of therapy (enzalutamide or docetaxel) in participants with mCRPC 9 metastatic castration resistant prostate cancer.
To learn more about MEVPRO-1 and how you can join contact our research office at (314) 289-7690
The study is funded by our Foundation through Pfizer
Study Coordinators: Carley Browning
The purpose of this study is to learn about the investigational medicine called PH-06821497 (mevrometostat) in men with mCRPC who were previously treated with abiraterone acetate for prostate cancer.
This study is to evaluate whether the addition of EZH2 (enhancer of zeste homologue-2) inhibition to enzalutamide can reverse anti-androgen resistance, thereby in increasing the duration of clinical benefit of enzalutamide in participants who have previously been treated with abiraterone. This Phase 3 randomized study (C2321014) is designed to demonstrate the PT-06821497 plus enzalutamide provides superior clinical benefit compared to physician's choice of therapy (enzalutamide or docetaxel) in participants with mCRPC 9 metastatic castration resistant prostate cancer.
To learn more about MEVPRO-1 and how you can join contact our research office at (314) 289-7690
The study is funded by our Foundation through Pfizer